Related Experiment Video

Updated: May 4, 2026

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

5.8K

Graves orbitopathy: a perspective

Petros Perros1, Gerasimos E Krassas

  • 1Endocrine Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK. petros.perros@newcastle.ac.uk

Nature Reviews. Endocrinology
|May 8, 2009
PubMed

Insights

Recent advances improve understanding of Graves orbitopathy (GO) pathogenesis and treatment. Intravenous steroids and orbital radiotherapy are effective, with immunotherapies like rituximab showing promise for managing this autoimmune eye condition.

Area of Science:

  • Endocrinology and Immunology
  • Ophthalmology
  • Autoimmune Diseases

Background:

  • Graves orbitopathy (GO) is an autoimmune condition affecting the eyes.
  • Understanding the pathogenesis, including the roles of TSH and IGF-1 receptors, has advanced.
  • Optimal management strategies are crucial for patient outcomes.

Purpose of the Study:

  • To summarize recent advancements in understanding Graves orbitopathy pathogenesis.
  • To review current optimal treatment strategies for GO.
  • To explore emerging immunotherapies for GO management.

Main Methods:

  • Review of recent scientific literature on Graves orbitopathy.
  • Analysis of established treatment guidelines from the European Group on Graves' Orbitopathy.
  • Evaluation of evidence for steroid therapies, radiotherapy, and immunotherapies.

Main Results:

  • Intravenous steroid pulses are superior to other steroid regimens for GO treatment.
  • Orbital radiotherapy shows efficacy in a subset of patients with eye muscle dysfunction.
  • Rituximab is a promising immunotherapy agent currently under investigation for GO.

Conclusions:

  • Current understanding of GO pathogenesis has improved significantly.
  • Established treatments like IV steroids and radiotherapy offer effective management options.
  • Immunotherapies, particularly rituximab, represent a potential future direction for GO treatment.

More Related Videos

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.7K
Grossing of Non-neoplastic Globes, Including Fetal Eyes05:15

Grossing of Non-neoplastic Globes, Including Fetal Eyes

Published on: May 30, 2025

751

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
30
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
28
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26